Skip to main content
NVDA-2.21%AAPL+3.23%GOOGL+0.69%MSFT-0.05%AMZN-0.34%TSM-1.33%SPCX-0.03%AVGO-0.71%META-1.38%TSLA-1.05%SKHY-4.40%MU-4.51%BRK-B0.00%LLY+0.20%JPM-0.47%WMT-0.02%AMD-3.07%V-0.09%XOM+0.70%ASMLa-1.66%JNJ-0.17%INTC-5.02%MA-0.44%0700.HK-1.94%1398.HK+0.79%ORCL-4.69%ABBV+1.24%BAC-0.28%CSCO-1.37%CVX-0.36%COST-0.07%KO+0.54%LRCX-5.02%CAT-1.31%AP2d-1.55%0005.HK-0.78%AMAT-2.58%UNH-0.95%HSBA.L-1.30%DELL-4.12%PG+0.24%MS-1.02%GE-0.58%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX-0.11%HD-1.73%0939.HK+1.66%GS-1.19%NZDJPY-2.63%AUDJPY-1.87%CHFJPY-1.61%NZDCAD-1.45%EURNZD+1.44%NZDUSD-1.42%GBPNZD+1.37%GBPJPY-1.27%EURJPY-1.25%USDJPY-1.24%CADJPY-1.21%NZDCHF-1.06%USDZAR+1.03%USDSEK+0.94%USDNOK+0.90%EURZAR+0.85%AUDNZD+0.79%GBPZAR+0.76%EURSEK+0.75%EURNOK+0.72%USDTHB+0.69%AUDCAD-0.69%AUDDKK-0.66%AUDUSD-0.64%EURAUD+0.63%CHFSEK+0.60%USDMXN+0.59%GBPAUD+0.59%CHFNOK+0.57%AUDSGD-0.56%USDPLN+0.44%NZDSGD-0.42%GBPTRY+0.41%NOKJPY-0.40%CADCHF+0.39%USDCHF+0.38%EURCHF+0.36%GBPCHF+0.33%GBPHKD+0.32%GBPMXN-0.28%USDSGD+0.28%AUDCHF-0.26%EURPLN+0.26%SGDJPY+0.22%EURHKD-0.19%USDDKK+0.18%USDILS+0.16%NZDMXN-0.13%USDTRY+0.11%EURSGD+0.10%USDCNH+0.10%GBPCAD-0.08%EURCNH-0.06%AUDNOK+0.06%PLNJPY+0.06%EURCZK-0.05%CHFSGD-0.05%EURGBP+0.04%EURCAD-0.04%USDCOP-0.04%GBPUSD-0.03%USDCAD-0.02%USDHKD+0.02%EURUSD-0.01%GBPSGD+0.01%EURDKK0.00%XPTUSD-6.19%UKOIL+5.78%USOIL+5.62%XAGUSD-5.44%GAGUSD-5.44%HG1-4.88%XAUUSD-1.74%GAUUSD-1.74%XNGUSD+1.54%COTTON0.00%SUGAR0.00%S10.00%BTCUSD-1.32%ETHUSD+0.06%USDTUSD-0.02%XRPUSD-2.73%SOLUSD-1.47%TRXUSDT+0.24%ZECUSDT-9.00%DOGEUSD-2.27%XMRUSDT+0.46%LINKUSD-1.23%XLMUSD-1.37%BCHUSDT-9.63%LTCUSD-1.63%UNIUSD-0.90%TONUSD+24.88%HBARUSDT-1.99%SUIUSD-4.06%TAOUSDT-5.37%AAVEUSD-1.98%DOTUSDT-1.56%ICPUSDT-0.36%ONDOUSDT-3.20%WLDUSDT-3.15%ATOMUSDT-2.87%ARBUSDT-0.50%JUPUSDT-3.39%INJUSDT-1.98%STXUSDT-4.53%FETUSDT-2.62%TIAUSDT-1.13%PYTHUSDT-1.05%SEIUSDT-6.02%IMXUSDT-3.85%GRTUSDT-3.55%WIFUSDT-4.89%OPUSDT-4.00%POLUSDT-4.48%IOTAUSDT-3.81%AXSUSDT-2.04%FARTCOINUSDT-2.74%EOSUSDT-2.66%DYDXUSDT-2.31%ORDIUSDT-0.73%GALAUSDT-3.09%NOTUSDT-2.97%RONINUSDT-2.64%NVDA-2.21%AAPL+3.23%GOOGL+0.69%MSFT-0.05%AMZN-0.34%TSM-1.33%SPCX-0.03%AVGO-0.71%META-1.38%TSLA-1.05%SKHY-4.40%MU-4.51%BRK-B0.00%LLY+0.20%JPM-0.47%WMT-0.02%AMD-3.07%V-0.09%XOM+0.70%ASMLa-1.66%JNJ-0.17%INTC-5.02%MA-0.44%0700.HK-1.94%1398.HK+0.79%ORCL-4.69%ABBV+1.24%BAC-0.28%CSCO-1.37%CVX-0.36%COST-0.07%KO+0.54%LRCX-5.02%CAT-1.31%AP2d-1.55%0005.HK-0.78%AMAT-2.58%UNH-0.95%HSBA.L-1.30%DELL-4.12%PG+0.24%MS-1.02%GE-0.58%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX-0.11%HD-1.73%0939.HK+1.66%GS-1.19%NZDJPY-2.63%AUDJPY-1.87%CHFJPY-1.61%NZDCAD-1.45%EURNZD+1.44%NZDUSD-1.42%GBPNZD+1.37%GBPJPY-1.27%EURJPY-1.25%USDJPY-1.24%CADJPY-1.21%NZDCHF-1.06%USDZAR+1.03%USDSEK+0.94%USDNOK+0.90%EURZAR+0.85%AUDNZD+0.79%GBPZAR+0.76%EURSEK+0.75%EURNOK+0.72%USDTHB+0.69%AUDCAD-0.69%AUDDKK-0.66%AUDUSD-0.64%EURAUD+0.63%CHFSEK+0.60%USDMXN+0.59%GBPAUD+0.59%CHFNOK+0.57%AUDSGD-0.56%USDPLN+0.44%NZDSGD-0.42%GBPTRY+0.41%NOKJPY-0.40%CADCHF+0.39%USDCHF+0.38%EURCHF+0.36%GBPCHF+0.33%GBPHKD+0.32%GBPMXN-0.28%USDSGD+0.28%AUDCHF-0.26%EURPLN+0.26%SGDJPY+0.22%EURHKD-0.19%USDDKK+0.18%USDILS+0.16%NZDMXN-0.13%USDTRY+0.11%EURSGD+0.10%USDCNH+0.10%GBPCAD-0.08%EURCNH-0.06%AUDNOK+0.06%PLNJPY+0.06%EURCZK-0.05%CHFSGD-0.05%EURGBP+0.04%EURCAD-0.04%USDCOP-0.04%GBPUSD-0.03%USDCAD-0.02%USDHKD+0.02%EURUSD-0.01%GBPSGD+0.01%EURDKK0.00%XPTUSD-6.19%UKOIL+5.78%USOIL+5.62%XAGUSD-5.44%GAGUSD-5.44%HG1-4.88%XAUUSD-1.74%GAUUSD-1.74%XNGUSD+1.54%COTTON0.00%SUGAR0.00%S10.00%BTCUSD-1.32%ETHUSD+0.06%USDTUSD-0.02%XRPUSD-2.73%SOLUSD-1.47%TRXUSDT+0.24%ZECUSDT-9.00%DOGEUSD-2.27%XMRUSDT+0.46%LINKUSD-1.23%XLMUSD-1.37%BCHUSDT-9.63%LTCUSD-1.63%UNIUSD-0.90%TONUSD+24.88%HBARUSDT-1.99%SUIUSD-4.06%TAOUSDT-5.37%AAVEUSD-1.98%DOTUSDT-1.56%ICPUSDT-0.36%ONDOUSDT-3.20%WLDUSDT-3.15%ATOMUSDT-2.87%ARBUSDT-0.50%JUPUSDT-3.39%INJUSDT-1.98%STXUSDT-4.53%FETUSDT-2.62%TIAUSDT-1.13%PYTHUSDT-1.05%SEIUSDT-6.02%IMXUSDT-3.85%GRTUSDT-3.55%WIFUSDT-4.89%OPUSDT-4.00%POLUSDT-4.48%IOTAUSDT-3.81%AXSUSDT-2.04%FARTCOINUSDT-2.74%EOSUSDT-2.66%DYDXUSDT-2.31%ORDIUSDT-0.73%GALAUSDT-3.09%NOTUSDT-2.97%RONINUSDT-2.64%
IP

Indivior Pharmaceuticals Inc (INDV)

NASDAQ • Healthcare

$34.77
+$0.45 (+1.3%)
Market open

Last close at September 9, 2026 at 20:00 UTC

Open$34.32
Previous Close$34.77
Day Range$33.92 - $34.8
Avg. Volume (3M)1.9M
Market Cap$4.2B
P/E Ratio12.2
52 Week Range
$22.22$42.81
Next EarningsIn 49 daysOct 29, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$343M100%
Gross Profitminus cost of goods$294M86%
Operating Incomeminus R&D and overhead$160M47%
Net Incomeminus taxes and the rest$122M36%

In plain terms: out of every $100 in revenue, Indivior Pharmaceuticals Inc keeps $36 as net profit.

Fundamentals & Financials

Revenue (TTM)
$1.3B
Net Income (TTM)
$354.9M
EPS (TTM)
$2.84
ROA (TTM)
28.79%
Current Ratio
0.84

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

+26.2%Q1 2026$0.82
+50.0%Q2 2026$0.96
+32.3%Q3 2026$1.15
Next

Oct 29

in 49 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Beat +32.3%

Indivior Pharmaceuticals topped consensus on both revenue and adjusted EPS in the second fiscal quarter of 2026, reported August 3, as revenue of $343.0 million topped the $306.2 million estimate, +12.0%, and rose 13.6% from $302.0 million a year ago. Adjusted EPS of $1.15 topped the $0.87 estimate, +32%, while net income climbed 577.8% to roughly $122.0 million from $18.0 million a year earlier. Gross margin was near 86% and operating margin around 47%, with operating income at about $160.0 million. The quarter generated operating cash flow of about $229.0 million, and the company repurchased $176.0 million of stock. Consensus for the next period calls for EPS of $1.06 on revenue of $329.4 million.

View full earnings history

About Indivior Pharmaceuticals Inc

Indivior Pharmaceuticals Inc is a healthcare holding company that researches, produces, and distributes buprenorphine-based prescription medications designed to treat opioid dependence. Listed on the NASDAQ as INDV, it generated $1.2 billion of revenue in FY2025 from a portfolio centered on addiction-treatment therapies.

Name
Indivior Pharmaceuticals Inc
CEO
Joseph J. Ciaffoni
Website
www.indivior.com
Industry
Healthcare
Year Founded
2014
Employees
833

Today's Snapshot

AI-generated

So far today, INDV is trading 1.3% lower at 34.31, in line with a weaker sector. Indivior plans to merge with Supernus Pharmaceuticals, a drugmaker.

Trading Volume

Below 10d avg (1.8M)

891.7K

vs S&P 500 Today

Underperforming Market

-0.71%

Updated: September 10, 2026 at 19:25 UTC

Technical Indicators

1 Buy1 Neutral6 Sell
INDV is displaying a strong bearish technical stance with the price near 34.13 trading below most short-, medium- and 200-day averages, and intraday levels such as VWAP and the pivot also signaling weakness. Trend strength is strong with ADX near 40, while momentum indicators are negative—MACD and price momentum are down and RSI is close to oversold—despite very oversold oscillators showing short-term buy readings. Volume trends are negative and volatility is moderate with an ATR around $1.10. Technical takeaway: Strong Sell.
All signals
  • EMA (5 indicators)$34.77 - $37.24
    Sell
  • RSI (14)31.34
    Neutral
  • Stochastic %K (14, 3, 3)10.40
    Buy
  • MACD Level (12, 26)-1.18
    Sell

Peers & Related Assets

PRAXPraxis Precision Medicines, Inc.
$345.3-2.0%
CRNXCrinetics Pharmaceuticals, Inc.
$84.950.0%
LNTHLantheus Holdings, Inc.
$100.7+0.3%
AMRXAmneal Pharmaceuticals, Inc.
$17.25+1.2%
ACADACADIA Pharmaceuticals Inc.
$27.68+0.4%
VKTXViking Therapeutics, Inc.
$32.7-2.9%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.